Sclerosing Epithelioid Fibrosarcoma, from the CureRays guide library.

Sclerosing epithelioid fibrosarcoma is a rare, slow-but-stubborn soft-tissue sarcoma defined by a specific gene fusion, treated mainly with wide surgery and radiation because it resists ordinary chemotherapy and tends to come back or spread late.

What it is.

Sclerosing epithelioid fibrosarcoma (SEF) is a rare soft-tissue sarcoma — a cancer of the body's connective tissue — that usually appears as a firm, deep mass in the limbs, trunk, or around bone. Under the microscope its cells sit in a dense, scar-like (sclerotic) background, which gives it its name and can make it tricky to diagnose. Most cases carry a characteristic gene fusion involving the FUS or EWSR1 gene with CREB3L1 or CREB3L2, and a protein marker called MUC4 helps pathologists confirm it. SEF often grows slowly but is stubborn: it tends to recur where it started and can spread to the lungs or bone, sometimes many years later. Because it generally resists standard chemotherapy, treatment relies on complete surgical removal, frequently combined with radiation, and on long-term follow-up.

How radiation treats it.

Radiation damages the DNA inside cancer cells so they can no longer divide. For sclerosing epithelioid fibrosarcoma, which tends to come back at the original site, radiation is an important partner to surgery: given before or after the operation, it treats the microscopic cells extending beyond the visible tumor and lowers the chance of local recurrence. For isolated spots of spread in the lung or bone, focused techniques like SBRT can control disease without another operation. Modern planning shapes the dose tightly around the target — and proton therapy can further spare sensitive nearby structures. Radiation is painless during delivery, given over a planned course, and external-beam treatment leaves no radioactivity in the body.

The ways we can treat it.

Pre- or post-operative external-beam radiation. Shaped beams treat the tumor and a margin around it to destroy microscopic cells the surgeon cannot see, lowering the chance of local return.

Proton therapy (selected sites). When the tumor is near the spine, pelvis, or other sensitive structures, protons concentrate the dose on the target while sparing nearby organs.

Stereotactic body radiation (SBRT). Delivers a few high, focused doses to an isolated area of lung or bone spread, controlling it without surgery.

Questions we hear often.

Is this an aggressive cancer? SEF often grows slowly, but it is stubborn: it has a notable tendency to come back where it started and can spread to the lungs or bone, sometimes years later. That mix of slow growth and persistence is why complete surgery, radiation, and long-term follow-up are all important.

Why isn't chemotherapy used much? SEF generally does not respond well to standard chemotherapy. As a result, treatment relies on surgery and radiation for local control, and chemotherapy is reserved for widespread disease — often within a clinical trial testing newer, targeted approaches.

How long should I be followed after treatment? Longer than for many cancers. Because SEF can return or spread well beyond the usual five-year window, doctors recommend extended monitoring with periodic imaging of the original site and the chest, so that any recurrence is caught early when it is most treatable.

This guide is informational only. It is not medical advice — please confirm anything here with your care team.